Michael Schmitz
Stock Analyst at Guggenheim
(2.12)
# 2,949
Out of 4,980 analysts
7
Total ratings
66.67%
Success rate
3.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Reiterates: Buy | $45 | $38.39 | +17.22% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $45.88 | +78.73% | 2 | Oct 28, 2024 | |
| MRUS Merus | Maintains: Buy | $93 → $111 | $68.35 | +62.40% | 2 | Oct 1, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $7.92 | +405.05% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.05 | - | 1 | Jan 3, 2023 |
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $38.39
Upside: +17.22%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $45.88
Upside: +78.73%
Merus
Oct 1, 2024
Maintains: Buy
Price Target: $93 → $111
Current: $68.35
Upside: +62.40%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $7.92
Upside: +405.05%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.05
Upside: -